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Hepatic encephalopathy is a frequent and serious complication of liver cirrhosis; the pathophysiology of this complication is not
fully understood although great efforts have beenmade during the last years.There are few prospective studies on the epidemiology
of this complication; however, it is known that it confers with high short-termmortality. Hepatic encephalopathy has been classified
into different groups depending on the degree of hepatic dysfunction, the presence of portal-systemic shunts, and the number of
episodes. Due to the large clinical spectra of overt EH and the complexity of cirrhotic patients, it is very difficult to perform quality
clinical trials for assessing the efficacy of the treatments proposed. The physiopathology, clinical manifestation, and the treatment
of HE is a challenge because of the multiple factors that converge and coexist in an episode of overt HE.
1. Introduction
Hepatic encephalopathy (HE) is a disturbance in the central
nervous system (CNS) function due to hepatic insufficiency
or portal-systemic shunting. HE causes a spectrum of neuro-
logicmanifestations that develop in associationwith different
liver diseases [1]. A common link is the potential reversibility
of the neurologicmanifestations once the abnormality of liver
function is corrected. The shunting of blood from the portal
venous bed into the systemic circulation is considered a key
element of HE. There are a series of neurological disorders
associated with liver disease that are not considered HE.This
disorders may share a common pathogenetic mechanism,
for example, brain and liver damage caused by alcohol or
copper (Wilson’s disease). HE must also be differentiated
from neurologic disturbances caused directly by bilirubin
accumulation (kernicterus), cerebral hemorrhage secondary
to disorders of coagulation caused by the liver disease, or
other abnormalities that are not secondary to liver failure.
The nomenclature that several authors have used for HE
is confusing. For this reason several efforts have been made
to reach a consensus, especially for the design of clinical
trials [2]. Despite this limitation, from a clinical perspective,
HE is generally classified according to the underlying liver
disease and the evolution of the neurological manifestations
(Table 1). The most frequent liver disease is cirrhosis, usually
accompanied by extrahepatic portal-systemic shunts (spon-
taneous or surgical). HE also can be seen in acute liver failure,
where it constitutes the hallmark of the disease. In rare cases,
HE develops in the absence of any sign of parenchyma liver
disease and is caused solely by portal-systemic shunting of
congenital or surgical origin.
The neurologic manifestations are variable. The most
distinctive presentation is an acute episode characterized by
the sudden onset of confusion that can evolve into coma.
Neuromuscular abnormalities are common, with the most
characteristic one being the presence of asterixis; pyrami-
dal signs may also be present. The term chronic hepatic
encephalopathy is reserved for patients who have frequent
episodes of episodic encephalopathy or persistent cognitive
(memory loss, confusion, and disorientation) or neuromus-
cular disturbances (tremor, apraxia, and rarely paraplegia).
Minimal hepatic encephalopathy corresponds to those neu-
rologic manifestations that are not obvious on clinical exam-
ination but are detected by the demonstration of abnormal
neuropsychological or neurophysiological tests [3].
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Table 1: Classification of hepatic encephalopathy.
HE associated to an acute liver failure
HE associated to a portosystemic shunt without hepatic cirrhosis
HE associated to cirrhosis and portal hypertension
Episodic Chronic Minimum
↙ ↘ ↙ ↘
Primary Secondary Mild Severe
HE: hepatic encephalopathy.
2. Pathogenesis
2.1. General Aspects. Different hypotheses have been pro-
posed to explain the changes in mental state that occur in
HE. Ideally, such a theory should explain the relation between
liver and neurological abnormalities. However, establishing
such relations is difficult, in part, because of limitations in
the methods available to study brain function in humans and
also due to an insufficient knowledge of the neurobiological
basis of behavior. Nevertheless, there is a generalized con-
sensus that the validation of a hypothesis should explain the
mechanismof action of a precipitating factor andhow specific
therapies improve HE [4].
A common pathogenetic notion is that HE is caused by
substances that under normal circumstances are efficiently
metabolized by the liver, rather than an insufficient pro-
duction of substrates that could be essential for neurologic
function. Under this light, portal-systemic shunting plays a
critical role, as themain impact of this circulatory disturbance
is on the concentration of gut-derived substances that are
highly cleared by the liver. Studies of cross-perfusion in
animals with experimental HE and liver support systems in
humans have shown that clearance of toxic substances present
in the blood is more important to improve mental function
than the synthetic capacity of the support system [5]. In
patients with liver disease, these toxic substances reach the
systemic circulation as a result of portal-systemic shunting
or reduced hepatic clearance and produce deleterious effects
on brain function. Once the toxic substances are in neural
tissues, a large number of neurochemical changes occur that
affect multiple neurochemical pathways, each affected to a
variable extent [6].
Historical hypothesis have ranged from unifying theories
[7] to the notion of HE as a multifactorial process [8]. As
in other metabolic encephalopathies, general neuronal dys-
function results in abnormalities of consciousness. However,
in contrast to other conditions that affect consciousness
(such as hypoglycemia), where neuronal function is primarily
affected, the cell that is abnormal in HE corresponds to the
astrocyte that shows characteristic changes in morphology
and function. This feature has led to the interpretation that
HE is mostly a disturbance of consciousness secondary to
altered communication between the astrocyte and the neuron
[9]. Alternative views, such as the GABA (𝛾-aminobutyric
acid) theory, explain the spectrum of HE through the
direct effect of one toxin on a key aspect of neurological
function [10]. Other paradigms arise from the experimental
observation that different toxins enhance the negative effects
of ammonia on consciousness (synergistic theory) [11]. This
concept has been expanded to include the contribution of
systemic inflammation to hepatic encephalopathy [12], aswell
as alterations in the cerebral blood flux and in the oxidative
metabolism [13].
2.2. Ammonia. Ammonia is considered an important factor
in the pathogenesis of HE.The data that support the involve-
ment of ammonia are as follows. (a) Ammonia is produced
by the gut, and an important amount is of bacterial origin
[12]. (b) The concentration of ammonia in portal blood is
high, and a high degree of extraction occurs in the liver
[14]. (c) Concentrations of ammonia are high in the systemic
circulation and in the cerebrospinal fluid of patients with HE
[15]. (d) Precipitating factors cause elevations in the blood
level of ammonia or result in exposure of brain tissue to
ammonia [12]. (e) Strategies that decrease the level of blood
ammonia are of benefit [16].
Ammonia is generated in different tissues from the break-
down of amino acids and other nitrogenous substances.
Under normal physiological conditions, ammonia enters the
portal circulation from the gastrointestinal tract, where it
derives from colonic bacteria and from the deamidation of
glutamine in the small bowel. Traditionally, absorption was
viewed as the result of passive diffusion; more recent studies
indicate the presence of specific ammonia transporters [16].
Regardless of the mechanism of absorption, ammonia
reaches high concentration in the portal blood and undergoes
a high first-pass hepatic extraction (−80%). In the liver,
ammonia is transformed in the periportal hepatocytes into
urea (a high-capacity and low-affinity system) and in the cen-
trovenular hepatocytes into glutamine (a low-capacity and
high-affinity system). Urea is quantitatively the most impor-
tant product of ammoniametabolism and elimination. Circu-
lating urea diffuses into the intestine (−40%), where it under-
goes hydrolysis into ammonia through ureases present in
colonic bacteria. Urinary elimination of nitrogen in the form
of urea is a route of ammonia disposal from the organism.
In addition to the intestine and the liver, kidney and
muscle contribute to regulating the arterial ammonia level
[17]. In muscle, ammonia is transformed into glutamine
through the action of glutamine synthetase. Experiments
in normal volunteers showed that 50% of injected 15N-
ammonia is removed by the muscles [18]. The ability of
the muscle to “fix” appreciable amounts of blood-borne
ammonia becomes important to regulate arterial ammonia
in case of liver failure and highlights the importance of
maintaining an adequate muscular mass in patients with
HE. It is generally accepted that at rest skeletal muscle is an
ammonia-consuming organ. However, during moderate to
heavy exercise, the muscle releases ammonia [19]. The kid-
neys generate ammonia from the deamination of glutamine,
a step involved in the regulation of arterial and urinary pH. A
small fraction of renal ammonia is released into the systemic
circulation; urinary ammonia excretion may be affected by
dehydration and increases in conditions of hyperammonemia
[20]. Notwithstanding the role of peripheral organs, the main
factors resulting in the increase in blood ammonia in liver


























Figure 1: Physiopathology of hepatic encephalopathy. Cordoba Semin Liv Dis 2008. GLN: glutamine; GLU: glutamate; GNase: glutamine
synthetase; BBB: blood brain barrier.
urea and glutamine and the bypass of first-pass hepatic
metabolism via portal-systemic shunts.
Patients with HE have an increased diffusion of ammonia
into the brain [12], though recent studies using sophisticated
PET techniques have questioned this tenet [13, 21]. Variations
in the passage of ammonia across the blood brain barrier
may explain the poor relationship between the level of arterial
ammonia and the degree of HE; nonetheless, the relation
between plasma ammonia levels and cerebral dysfunction
seems to be clear in patients with acute liver failure in which
plasma ammonia have a direct correlation with the presence
of intracranial hypertension and death [22, 23] (Figure 1).
This relation may be related to the induction of brain edema
by ammonia or simply be an indicator of the severity of
liver failure. During HE episodes in cirrhosis, ammonia
shows a huge interpersonal variability. This may highlight
the importance of additional factors that participate in the
pathogenesis of HE. Among them, those more important
appear to be inflammatory mediators.
2.3. Glutamine. Most recently, glutamine has been shown to
have a key role in the brain toxicity induced by ammonia. It
has long been accepted that the conversion of glutamate to
glutamine, catalyzed by glutamine synthetase, a cytoplasmic
enzyme largely localized in astrocytes in brain, represents the
principal way of cerebral ammonia detoxification. Much of
the newly synthesized glutamine is subsequentlymetabolized
in mitochondria by phosphate-activated glutaminase, yield-
ing glutamate and ammonia. In this manner, glutamine is
transported in excess from the cytoplasm to mitochondria
serving as a carrier of ammonia. It has been proposed that the
glutamine-derived ammonia interferes with mitochondrial
function giving rise to excessive production of free radicals
and induction of the MPT, two phenomena known to bring
about astrocyte dysfunction, including cell swelling [24].This
hypothesis is supported by neuroimaging studies [25] that
had shown increased levels of brain glutamine during the HE
episode that decreased when the episode had been recovered.
2.4. GABA Agonists. Several lines of evidence support the
presence of activated GABAergic tone in HE [26]. One of
the postulated mechanisms for this effect is the increased
availability of agonist ligands of the GABA receptor com-
plex, a key inhibitory neurotransmitter in the brain. The
term natural benzodiazepines has been coined for a group
of substances of nonpharmacological origin that bind to
the benzodiazepine site of the GABA receptor, where they
can act as agonist or antagonist. These substances, which
are poorly characterized from a chemical and functional
perspective, have been reported to be present in a variety
of human tissues in normal conditions and to purportedly
accumulate in the brain of patients with HE [27]. It has been
proposed that natural benzodiazepines with agonist effects
on the GABA receptor induce a decrease of consciousness
in HE. However, not all the benzodiazepine ligands found
in HE have agonist effects on the GABA receptor (e.g.,
diazepam binding inhibitor). Furthermore, alternative routes
of activation of GABA neurotransmission may be present.
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These include direct and indirect effects of ammonia on the
affinity of GABA receptors to its natural ligand [7]. Ammonia
may also result in an increased density of peripheral-type
benzodiazepine receptors (PTBRs), present in astrocytic
mitochondria and whose activation results in the synthesis of
neurosteroids, powerful ligands of neuronal GABA receptors
[28, 29].
Several arguments have been proposed in favor of a role
for natural benzodiazepines in HE. The most relevant is the
observation of an improvement of mental state after the
administration of flumazenil (a benzodiazepine receptor
antagonist) in some patients with advanced stages of HE
that have not consumed benzodiazepines of pharmacological
source [30]. However, the beneficial effects of flumazenil,
usually mild and transient, are only seen in a subgroup of
patients. One of the main limitations of this theory is the lack
of an explanation of the mechanism by which natural benzo-
diazepines increase in HE. A study in rats with experimental
HE showed generation in the intestinal flora of precursors
of natural benzodiazepines [31]. These precursors would be
transformed into natural benzodiazepines in the brain and
accumulate secondarily to liver failure. However, additional
studies in humans are lacking in order to confirm the link
between intestinal flora, liver function, natural benzodi-
azepines, and HE. An alternative source of natural benzo-
diazepines could be hemoglobin; metabolites of hemoglobin
that mimic benzodiazepines have been described [32].
2.5. Manganese. Manganese is probably involved in the
development of parkinsonian manifestations in HE, but its
role in other neurological manifestations is uncertain [33].
The concentration of manganese is elevated in plasma of
patients with cirrhosis and in the brain of patients who die
withHE.Hypermanganesemia is the result of portal-systemic
shunting and reduction in biliary excretion [34]. Patients
with cirrhosis typically exhibit a hyperintense signal in the
globus pallidus that has been attributed to the preferential
accumulation of manganese in basal ganglia. However, some
studies have failed to show a good association between the
intensity of the signal in basal ganglia and neurological
manifestations of HE [35]. Nevertheless, similarities to the
clinical and radiological features of manganese intoxication
suggest that the increase in manganese in cirrhosis causes
the extrapyramidal signs of chronic HE throughmechanisms
that impair dopaminergic neurotransmission. The effect of
manganese removal on the neurological signs and symptoms
of chronic HE has not been evaluated.
2.6. Astrocytes. Experimental and pathological evidence
point at astrocytes as the main neurological cell affected in
[36]. The distinctive morphologic alteration is the Alzheimer
type II astrocytic change, which is characterized by a cell with
enlarged, pale nuclei with peripheral margination of chro-
matin and often prominent nucleoli. Results of microscopic
studies of specimens from humans and experimental prepa-
rations suggest that the astrocytic changes are due to cellular
swelling.
Astrocytes occupy one third of the volume of the cere-
bral cortex. Their foot processes surround brain capillaries,
where they contribute to blood brain barrier function. This
anatomical organization forms a syncytium, where critical
metabolic supportive functions involved in the maintenance
and regulation of the extracellular microenvironment, such
as uptake of ions and neurotransmitters, influence neuronal
excitability and neurotransmission. A specific astrocyte func-
tion is the detoxification of ammonia through the amidation
of glutamate to glutamine.
Recent studies have emphasized a role for oxidative stress,
including nitrosative stress, as a critical factor in ammonia-
induced cell impairment through collapse of the inner mito-
chondrial membrane due to the opening of the permeability
transition pore. The collapse leads to mitochondrial dys-
function, energy failure, and additional free radical produc-
tion. The mitochondrial permeability transition is a Ca2+
dependent, cyclosporine A (CsA) sensitive process due to
the opening of a pore in the inner mitochondrial membrane
that leads to a collapse of ionic gradients and ultimately
to mitochondrial dysfunction. Through this mechanism,
ammoniamay result in astrocyte dysfunction andHE [24, 37–
39].
2.7. Neurotransmitter Systems. The improvement of neuro-
logical manifestations after the administration of a drug that
interacts with an individual transmitter system is an impor-
tant argument to support a pathogenic role for that system.
The first attempt to normalize the abnormalities of neuro-
transmission arose from the false neurotransmitter hypothe-
sis. The notion was to restore the abnormalities in the profile
of plasma amino acids and the transport of amino acids
across the blood brain barrier by administering branched
chain amino acids. Subsequent therapeutic attempts have
been focused on the brain itself and include stimulation of
dopaminergic transmission with bromocriptine or levodopa
[40] and blockage of GABA inhibitory neurotransmission
with flumazenil [30]. The results have not been remarkable,
highlighting the complexity of a paradigm where several
neurotransmitter systems are simultaneously affected. Still
these attempts indicate that it may be possible to treat hepatic
encephalopathy using drugs that act in the brain in addition
to measures that decrease the plasma level of a putative toxin.
Multiples abnormalities of neurotransmitter systems have
been described in HE. Glutamate neurotransmission, which
is clearly disturbed in animal models of HE [41], has been
proposed to play a role in the pathogenesis of HE. However,
supportive human data arise mostly from autopsied samples
[42] and pharmacological manipulation of glutamatergic
neurotransmission has not been attempted.
Decreasing the neurotransmitter activity will cause a
decrease in consumption of oxygen and glucose is accompa-
nied by a parallel decrease in cerebral blood flow [43]. Some
studies with humans have shown focal reductions of glucose
utilization that have been related to specific neurologic
manifestations [44]. However, the findings cannot separate
whether the decrease is the cause or the consequence of
the encephalopathy. The current interpretation is that, as in
other metabolic encephalopathies, the decrease in energy
consumption is secondary to the decrease in demand. An
increase in supply, as observed in some patients with high
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cerebral blood flow, especially among those with fulminant
hepatic failure, does not improve the mental state [45].
2.8. Brain Edema. Brain edema is a complication of ful-
minant hepatic failure, which can progress to intracranial
hypertension and death. Brain edema has been frequently
regarded as a distinct entity, dissociated from the neurological
features of HE. However, several lines of evidence relate brain
edema to HE [46]. Although intracranial hypertension is a
common problem in patients with fulminant hepatic failure
in coma, the development of high intracranial pressure (ICP)
in patients with cirrhosis in deep coma is only occasionally
documented [47].
Brain edema has been described in all situations of
acute hyperammonemia and has been associated to plasma
levels of ammonia in fulminant hepatic failure [23]. In the
experimental setting, brain swelling secondary to ammonia
infusion can be prevented with the administration of an
inhibitor of the synthesis of glutamine. Other factors, such
as hyponatremia, may enhance the effects of ammonia on
brain swelling [39]. In fulminant hepatic failure, an additional
factor that plays an important role in the development of
intracranial hypertension is the presence of abnormalities
of cerebral circulation. Cerebral vasodilatation and loss of
autoregulation are characteristic findings in fulminant hep-
atic failure [45].Themechanism that causes the abnormalities
of cerebral circulation has not been fully elucidated. They
appear to arise from a signal generated in the brain. Indeed,
measures that decrease cerebral vasodilatation are of clinical
benefit for patients with severe intracranial hypertension
[48]. In addition to differences in the cerebral circulation and
in the rate of exposure of the brain to ammonia, patients
with cirrhosis may activate compensatory mechanisms that
counteract osmotic changes in the brain [46]. Those with
hyponatremia are at higher risk for the development of
intracranial hypertension.
3. Clinical Features
3.1. Classification. The first step in the approach of HE is to
establish the presence or absence of underlying hepatic injury
as well as the degree of this injury.
The absence of hepatic cirrhosis leads to rule out the
presence of portal-systemic shunts being this vascular disor-
der the target of the treatment. HE associated to acute liver
failure confers a poor prognosis and it is the manifestation of
the end stage of this clinical condition involving prognostic
and therapeutic decisions. HE associated with cirrhosis and
portal hypertension can appear as an isolated episode with
or without precipitating event if the episodes resort in time
with a period free of event, it is defined as recurrent HE; if it
persist over time, it is defined as chronic HE. More recently,
another type of HE without apparent clinical disturbance
that required psychometric test for diagnose was defined as
minimum HE [49] (Table 1).
3.2. Acute Episode of Hepatic Encephalopathy. Acute HE can
appear as an isolated decompensation without worsening of
the hepatic function, as part as an acute-on-chronic liver
failure or as part as an acute liver failure without previous
hepatic disease. A special feature is the appearance of acute
HE in the context of portal-systemic shunts with or without
liver disease. Each specific case confers a different prognosis;
when the HE episode appears in the context of acute-on-
chronic liver failure a poor prognosis has been observed
(cumulativemortality of 55% in 9month) in contrast to when
it occurs as a simple decompensation, themortality was lower
25%. Acute liver failure in the absence of cirrhosis, deserve a
special mention, this entity has a high mortality and usually
requires a liver transplant.
The acute HE episode could be associated with a precip-
itating factor but in the majority of cases no precipitating
factor was identified.
An acute episode of HE is characterized by the devel-
opment of an acute confusional syndrome that includes
impaired mental state, neuromuscular abnormalities, fetor
hepaticus, and hyperventilation [2]. Variability is an impor-
tant feature; the clinical manifestations may fluctuate very
rapidly and oscillate from mild confusion to deep coma. The
onset is usually abrupt; HE develops over hours to days. Most
patients do not have significant neurological manifestations
before the onset of the acute episode of HE, unless they had
persistent HE.The evolution of an acute episode of HE tends
to parallel the course of liver function or the removal of the
precipitating factor. Patients usually recover fromHEwithout
major neurological deficits and are able to return to previous
activities.
Impairment of consciousness initially manifests as subtle
changes of personality or disturbances in the circadian
rhythm of sleep and wakefulness (insomnia during the night
and somnolence during the day). As HE progresses, the
manifestations include inappropriate behavior, disorienta-
tion, confusion, slurred speech, stupor, and coma. Some
patients may experience nausea and vomiting, especially if
there is a rapid evolution into coma.
Asterixis is a characteristic feature of HE that represents
the failure to actively maintain posture or position [2].
Asterixis is caused by abnormal function of diencephalic
motor centers that regulate the tone of agonist and antagonist
muscles, normally involved in maintaining posture [50].
The classic method of eliciting asterixis is by dorsiflexion
of the patient’s hand with the arms outstretched and fin-
gers separated. The postural lapse that occurs consists of a
series of rapid, involuntary, flexion-extension movements of
the wrist. Asterixis may be observed during any sustained
posture: tongue protrusion, dorsiflexion of the foot, or fist
clenching. Asterixis is not exclusive to HE and can occur
in other metabolic or structural encephalopathies (renal
failure, hypercapnia, and stroke affecting basal ganglia).
Asterixis does not occur in early or advanced HE. In coma,
asterixis disappears, but the patient may exhibit signs of
pyramidal involvement, such as exaggerated deep tendon
reflexes, hypertonia, or extensor plantar responses. Transient
decerebrate posturing and abnormal ocular movements may
occur in deep coma.
Fetor hepaticus is a peculiar pungent odor of the breath
that is often regarded as a component of HE. This odor
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has been attributed to dimethylsulphide, a volatile sulfur
compound that can be identified in the breath and serum of
patients with cirrhosis [51]. The presence of fetor hepaticus
is not constant; patients with cirrhosis without HE can
have this condition. Hyperventilation is also frequent, espe-
cially among patients with advanced HE. Hyperventilation
has been interpreted as a compensatory mechanism that
decreases the entrance of ammonia into the brain via a
decrease in arterial pH. It has also been related to elevated
levels of estrogens and progestogens [52].
3.3. Chronic Encephalopathy. Chronic encephalopathy encom-
passes two different situations: (a) the patient with relapsing
episodes of HE and (b) the patient with persistent neuro-
logical manifestations. This differentiation highlights the
more prominent clinical presentation, but in practice both
situations are difficult to separate. Some patients initially have
relapsing episodes and later have persistent symptoms. A
patient with pure relapsing HE or pure persistent HE is rare.
Furthermore, symptoms tend to fluctuate after the institution
of therapeutic measures or the occurrence of precipitating
events.
Relapsing episodes may be due to precipitating factors,
but in the majority of cases they are spontaneous or related
to discontinuation of medication. A history of constipation
is commonly elicited. The course of the acute episode does
not differ from the one previously described, except for a ten-
dency for an abrupt onset and resolution. Between episodes,
the patient can be perfectly alert and not showing any sign
of cognitive dysfunction. However, a careful neurological
exam and neuropsychological tests may reveal abnormalities.
Mild parkinsonian signs, characterized mostly by bradyki-
nesia without tremor [53], are probably the most common
manifestation between episodes.
Persistent HE refers to those manifestations that do not
reverse despite adequate treatment. In themajority of patients
with cirrhosis and prior episodes of acute HE and advanced
liver failure, a careful neurological examination may reveal
multiple mental and motor abnormalities. Most of these
abnormalities are subtle, such as increased muscle tone,
reduced mental or motor speed, dysarthria, hypomimia, lack
of attention, or apraxia. Psychometric tests may be helpful
in describing and quantifying the degree of impaired mental
function.
Persistent HE is considered severe when it impairs daily
activities. The most characteristic manifestations of severe
chronic HE are dementia, severe Parkinsonism, or myelopa-
thy in combination with other manifestations of neurologi-
cal involvement (ataxia, dysarthria, gait abnormalities, and
tremor). This clinical picture is seldom seen nowadays, as
a result of the availability of liver transplantation and the
limited number of patients that undergo surgical portal-
systemic shunts. Patients with hepatic dementia tend to have
fluctuating symptoms with periods of improvement and a
subcortical pattern. The initial manifestations are attention
deficits, visuopractic abnormalities, dysarthria, and apraxia.
Those with hepatic Parkinsonism may resemble Parkinson’s
disease, except for a symmetrical presentation and lack of sig-
nificant tremor. Hepatic myelopathy [54] is characterized by
a progressive spastic paraparesis accompanied by hyper-
reflexia and extensor plantar responses. Only a few patients
have sensory symptoms or incontinence. The pathogenetic
mechanisms of these complications are obscure. They have
associated neuronal loss, in the case of dementia, and
demyelination along the pyramidal tract in the case of
myelopathy. Although these lesions are difficult to reverse,
there have been descriptions of improvements after liver
transplantation [55], a challenge to the notion of irre-
versibility. The term hepatocerebral degeneration has been
occasionally used to describe such patients. However, this is
a neuropathological diagnosis applied to those brains that
exhibit substantial and irreversible loss of gray matter in
cortex and basal ganglia. It is preferable not to use it to
describe the clinical picture.
3.4. Fulminant Hepatic Failure. The clinical picture of HE in
acute liver failure parallel that of an acute episode of HE, an
acute confusional syndrome that evolves into coma.However,
in acute liver failure, brain edema leading to intracranial
hypertension and abnormalities of brain perfusion is critical
[56].
Brain edema does not result in clinical manifestations
unless intracranial hypertension is present, as the displace-
ment of brain tissue is the factor that results in neurological
symptoms. Intracranial hypertension may manifest as decer-
ebrate rigidity, myoclonus, seizures, mydriasis, bradycardia,
or arterial hypertension (the Cushing reflex). However, the
diagnosis of intracranial hypertension based on clinical signs
in unreliable, as they can be absent with pressures as high as
60mmHg [57] and difficult tomonitor because these patients
are intubated and paralyzed when they are in coma.
A major consequence of intracranial hypertension is the
effect on cerebral perfusion. The maintenance of cerebral
blood flow is critical to assure an adequate supply of oxygen.
The driving force in maintaining a stable blood flow is
the cerebral perfusion pressure, the arithmetical difference
between mean arterial pressure and ICP. When cerebral
perfusion pressure is less than 40mmHg, structural tissue
damage from brain ischemia may ensue. In spite of low
cerebral blood flow, an occasional patient may recover from
this situation without irreversible brain damage. Another
consequence of intracranial hypertension is the mechani-
cal compression of neighboring structures. The increase in
pressure causes displacement of brain tissue, resulting in
herniation and direct compression of the temporal lobe or
the cerebellum. Brain stem compression can result in sudden
respiratory arrest and circulatory collapse.
3.5. Minimal Hepatic Encephalopathy. Minimal HE, also
referred to by the terms latent or subclinical, is amild dysfunc-
tion of brain function that cannot be detected by standard
clinical examination [2, 3, 58]. This label was originally
applied to a group of individuals who performed abnormally
on psychometric tests but had essentially normal findings at
clinical examination. Psychometric tests are more sensitive
than clinical observation, as shown in other neuropsychiatric
diseases, such as dementia.
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Other techniques (EEG, evoked potentials, and neuroim-
aging) that are more sensitive than clinical examination to
reveal neurological impairment have also shown a stage of
minimal dysfunction. This stage is understood as part of a
continuous disorder that has several levels of severity, with
minimal HE being the mildest expression of HE. This inter-
pretation is supported by the observation of improvements
of minimal HE after the same therapeutic measures that are
addressed against overt HE [59] and the relationship between
minimal HE, ammonia levels, and liver function [60].
The diagnosis of minimal HE is arbitrary and can be
performed with neuropsychological or neurophysiological
tests. The most characteristic deficits are in motor and
attention skills [61]. Learning impairment, which has also
been described in experimentalmodels [62], appears to be the
consequence of attention deficits [63]. The depth of the psy-
chometric and the clinical examination necessary to diagnose
minimal HE is not defined. The frequency of the diagnosis
is very variable (30% to 84% of patients), depending on the
characteristic of the population being studied and the extent
of the psychometric evaluation. Some attempts have been
made to develop practical tools based on the design of short
batteries of neuropsychological tests, such as the PHES [64].
However, these batteries have not been fully standardized and
their use is still investigational. Critical flicker frequency, a
neurophysiological tool, has been proposed as a practical test
to assess low grade encephalopathy [65].
The importance of establishing the diagnosis of minimal
HE is unknown. Some studies have highlighted that minimal
HE may have an adverse impact on the ability to perform
daily activities and on health-related quality of life [66, 67].
However, many subjects are able to compensate for these
deficits [58]. From a practical point of view, a psychometric
evaluation may be adequate in those individuals whose
occupations demand attention and motor abilities. A report
of impaired driving in patients with minimal HE [68]
suggests the need to develop a therapeutic program for such
individuals. Benefits of the treatment, assessed bymonitoring
the neuropsychological response, should be weighed against
secondary side effects. There are no data on the effects of
therapy on health-related quality of life. Patients with cirrho-
sis and minimal HE have a clear tendency to develop overt
HE [69].Whether the institution of preventive measures may
decrease the risk of the progression to overt encephalopathy
has not been evaluated.Thepresence ofminimalHE indicates
worse prognosis, especially if associated with high blood
ammonia after the administration of glutamine [70].
4. Methods for the Assessment of
Hepatic Encephalopathy
4.1. GradingHepatic Encephalopathy. Grading ofHE is neces-
sary to assess the evolution of the condition and the response
to the effects of therapy. Several methods are based on
clinical findings or the combination of neurophysiological
and neuropsychological tests, but the simplest grading of HE
is based on clinical findings. TheWest Haven index is widely
used [71]. It is based on changes in consciousness, intellectual
function, and behavior (Table 2). The Glasgow coma scale
offers a system to monitor consciousness according to simple
and more objective parameters.This scale was initially devel-
oped for traumatic coma but has gained widespread use for
all forms of coma. It is probably more reliable than the West
Haven criteria but has the limitation that it is less sensitive in
quantifying the mildest forms of HE and is better suited for
advanced HE.
There are other scales widely used like the Clinical Hep-
atic Encephalopathy Staging Scale (CHESS); this scale evalu-
ated nine different items with a dichotomic answer, giving a
punctuation from 0 (no HE) to 9 (deep coma); the principal
disadvantage is the fact that the CHESS does not evaluate the
asterixis (Table 3) [72].
The portal-systemic encephalopathy index (PSE index)
has been used in many studies to assess the effects of ther-
apeutic measures. This index combines the assessment for
mental state, arterial ammonia, electroencephalography, the
number connection test, and estimation of the degree of
asterixis. An arbitrary weight of 3 is assigned to the mental
state and the other parameters are weighted. Concerns have
been raised about the arbitrary scoring system, the inclusion
of ammonia (a putative toxin), the feasibility of an arterial
puncture, and the assessment of the number connection test
in the evaluation of advanced HE. It is generally considered
that blood levels of ammonia, though separating groups
according to mean values [73], show wide dispersion in
individual values and are not useful to predict the severity of
HE and to monitor the response to therapy [74]. A consensus
has been reached indicating that the PSE index is not
adequate for clinical follow-up and is not recommended for
clinical trials.
4.2. Neuropsychological Tests. Themain role of neuropsycho-
logical tests is the diagnosis of minimal HE and the assess-
ment of cognitive function in patients with persistent HE.
Based on the most frequently found abnormalities, several
psychometric tests have been proposed to be the most ade-
quate for diagnosing HE [58, 60]. Neuropsychological tests
can be affected by multiple factors. It is important that the
neuropsychological assessment takes into consideration these
factors. Patients with clear signs of decreased arousal cannot
undergo testing. Care is needed to control comorbidities,
visual impairment, or cultural barriers. The test should be
adapted to the cultural characteristics of the population being
evaluated. Nomograms to compare the results should take
into consideration age and ideally the degree of education.
The patient undergoing testing should be sitting in a quiet
room with sufficient light. An important limitation of the
neuropsychological tests is the practice effect in follow-up
evaluation. Results of psychometric tests are affected by learn-
ing. Use of parallel versions can lessen this effect, but only few
tests have well-standardized versions.
Some short batteries specifically developed for HE may
be useful for the detection of abnormal cognition. However,
they donot substitute a formal neuropsychological evaluation
performed by an experienced neuropsychologist. ThePHES
is a battery of tests, specifically developed for the diagno-
sis of minimal HE [75]. Similar to the mini-mental state
examination for dementia, it can be useful for screening. The
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Table 2: TheWest Haven scale.
Stage TheWest Haven criteria Adapted West Haven criteria
0 No abnormality detected
Alert and attentive (oriented in time and space) without signs
of encephalopathy (neither dysarthria, ataxia, flapping tremor,
or obvious decrease in the speed of mental processing)
1
Trivial lack of awareness
Euphoria or anxiety
Shortened attention span
Impairment performance of addition
Alert and attentive, but with at least one of the following
signs: dysarthria, ataxia, flapping tremor, or obvious decrease in
the speed of mental processing
2
Lethargy or apathy
Minimal disorientation for time or place
Subtle personality change
Inappropriate behavior
Impaired performance of subtraction
Awake but inattentive: disoriented, somnolent, easy to distract,
and unable to perform easy mental tests (addition, subtraction,
and remember a list of numbers)
Patient’s speech is easy to understand
3
Somnolence to semistupor but responsive to verbal stimuli
Confusion
Gross disorientation
Marked somnolence or psychomotor agitation
Speech is difficult to understand
4 Coma (unresponsive to verbal or noxious stimuli)
Coma
The patient does not speak and does not follow simple
commands (such as raising an arm or opening the mouth)




(1) Does the patient know which month he/she is in (i.e., January,
February)? Yes No, he/she does not talk
(2) Does the patient know which day of the week he/she is in (i.e.,
Thursday, Friday, Sunday, etc.)? Yes No, he/she does not talk
(3) Can he/she count backward from 10 to 1 without making mistakes
or stopping? Yes No, he/she does not talk
(4) If asked to do so, does he/she raise his/her arms? Yes No
(5) Does he/she understand what you are saying to him/her? (Based
on the answers to questions 1 to 4) Yes No, he/she does not talk
(6) Is the patient awake and alert? Yes No, he/she is sleepy or fast asleep
(7) Is the patient fast asleep, and is it difficult to wake him/her up? No Yes
(8) Can he/she talk? Yes He/she does not talk
(9) Can he/she talk correctly? In other words, can you understand
everything he/she says, and he/she does not stammer? Yes No, he/she does not talk or does not talk correctly
Total score of the CHESS:
The total score is the sum of the answers to the nine items. Minimal score = 0; maximal score = 9.
Source: Semin Liver Dis © 2008Thieme Medical Publishers.
PHES combines 5 paper-pencil tests (line tracing tests, digit
symbol test, serial dotting test, number connection test A, and
number connection test B) that examine motor speed and
accuracy, visual perception, visual-spatial orientation, visual
construction, concentration, attention, and to a lesser extent
memory. The results of the battery are scored according to
nomograms from a group of healthy controls. A pathological
test result (diagnosis of minimal HE) has been set at −4
points, http://www.redeh.org/phesapp/datos.html.
Another useful test is the critical flicker frequency; this
test has the advantage that it is not conditioned by the cultural
or education level but it is necessary that the patient have
nonvisual impairment. It consists of placing a flashing light in
the visual field of the patient using specially designed glasses.
The light flashes initially at a high frequency, so it seems a
constant light. Gradually, the frequency decreases, and the
light becomes intermittent; that moment has to be identified
by the patient pressing a button [75, 76].
4.3. Neurophysiologic Tests. A large number of different neu-
rophysiological tests have been proposed for the diagnosis
and quantification of HE. Reports for and against the speci-
ficity of electrophysiological changes have been published
[77, 78]. These tests are most useful in documenting cerebral
dysfunction in difficult cases and possibly in monitoring
response to therapy. They have the advantage of not being
influenced by learning effects.Thus, theymay be better suited
for assessing effects of treatment than neuropsychological
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tests, especially for advanced stages of HE. For minimal to
mild HE, neurophysiological tests do not give information
about behavioral consequences, in contrast to the insight
provided by neuropsychological tests.
The standard electroencephalogram (EEG) shows slow-
ing of the frequency from the normal 8–13Hz to the delta
range below 4Hz. The change usually commences in the
frontal or central regions and progresses posteriorly. High
voltage, low-frequency (1.5 to 3Hz) waves with triphasic
appearance have been considered characteristic for HE.
However, they have been described in a variety of forms of
metabolic encephalopathy and are not specific to HE. Several
stages of evolution of EEG changes have been described in
HE and a fair correlation with clinical stages and ammonia
levels has been observed. The simplest EEG assessment is to
grade the degree of abnormality of the conventional tracing.
Computer-assisted frequency analysis of the EEG includes
evaluation of the mean dominant frequency and the power
of a particular EEG rhythm. Minor changes in the dominant
frequency occurs in patients with minimal HE [59].
Evoked responses are externally recorded potentials
reflecting discharges through neuronal networks after expo-
sure to specific stimuli [79]. Depending on the type of stim-
ulus and the pathway analyzed, they could be visual, somato-
sensory, or acoustic evoked potentials. Event-related poten-
tials using different stimuli represent endogenously task-
related cortical response reflecting the neural pathway
involved in awareness, learning, and decision-making pro-
cesses. Event-related potentials, such as the P300 evoked
potential, requires patient cooperation andwell-trained oper-
ators. Evoked potentials and event-related potentials are
considered more sensitive than the conventional EEG for
the diagnosis of mild forms of HE. They may be useful for
assessing the presence ofminimal ormildHE in patients with
cirrhosis who have memory loss or other mental symptoms.
4.4. Neuroimaging. At autopsy, the brains of cirrhotic
patients dying in HE do not showmajor anatomic abnormal-
ities, except for various degrees of atrophy.Thus, neuroimag-
ing studies that assess exclusively the morphologic structure
of the brain, such as computed tomography (CT), do not
detect specific abnormalities in HE. Brain atrophy, which is
depicted with CT, is more common in patients with long-
standing cirrhosis and chronic HE [80]. However, brain atro-
phy is not a specific abnormality of HE and may be related to
other factors than HE (alcoholism, age, and comorbid condi-
tions). Furthermore, as in other neurodegenerative diseases,
brain atrophy is not associated with neuropsychological per-
formance [79]. Conventional neuroimaging techniques are
insensitive in the detection of brain swelling thatmay develop
in some patients with cirrhosis and frequently complicates
HE in acute liver failure [81]. No studies have been able to find
a neuroimaging correlation of hepatocerebral degeneration
(cortical laminar necrosis and polymicrocavitation at the
corticomedullary junctions and in the striatum).
Magnetic resonance imaging (MRI) and spectroscopy
allow the acquisition of data on cerebral metabolic function
that are otherwise not available [29]. Proton MRI shows a
typical pallidal hyperintensity on T1-weighted images. This
abnormality is most frequently seen in patients with cirrhosis
with severe liver failure or long-standing portal-systemic
shunts and is absent or only minimally present in patients
with well-compensated cirrhosis and unimpaired neuropsy-
chiatric function. It can be also present in patients with
congenital shunts or portal thrombosis and normal liver
function [51]. No direct correlation between the magnitude
of pallidal hyperintensity and the grade of HE have been
found, but some studies have related pallidal hyperintensity
to parkinsonian manifestations [82]. Because of radiologic
similarities to manganese intoxication, it has been proposed
that pallidal hyperintensity is the consequence of the pref-
erential deposition of manganese in the basal ganglia. The
deposition of manganese in brain tissue would be secondary
to portal-systemic shunting and might be involved in the
parkinsonian symptoms found in persistent HE.
Proton magnetic resonance spectroscopy allows the
assessment of several brain metabolites (glutamine, gluta-
mate, myoinositol) that may be related to the pathogenesis
of HE. The level of glutamine, the product of ammonia
metabolism in astrocytes, is characteristically increased in
brain tissue. Although glutamine is considered neuronally
inactive, changes in its concentration may affect neuronal-
astrocytic trafficking and interact with glutamate neuro-
transmission [36]. The concentration of glutamine in cere-
brospinal fluid, an indicator of its level in brain tissue,
has been correlated to the stage of HE. Unfortunately, the
standard available systems, in which magnetic fields of 1.5
Teslas are used, do not allow a separation between the peaks
of glutamine (moderate to high increase in HE) and gluta-
mate (mild decrease in HE). Myoinositol has an important
role in osmotic regulation in astrocytes.The decrease in brain
myoinositol found by spectroscopy has been corroborated
in experimental preparations and has been attributed to a
compensatory response to the increase in intracellular osmo-
lality caused by the increased concentration of glutamine
[46]. Although the technique is insensitive to mild changes
in the concentration of metabolites, the abnormalities found
with spectroscopy have been related to neuropsychological
impairment and to liver function [83]. The role of proton
magnetic resonance in the diagnosis of HE has not been
investigated. Nevertheless, a completely normal study in a
patient suspected to suffer from HE is a strong argument
against this diagnosis.
Regional distribution of radionuclides in the brain has
been used to study cerebral blood flow, oxygen and glucose
consumption, neurotransmitter utilization, and availability
of neuronal receptors. The results of some of these studies
are controversial [84]. Although they may help in the under-
standing of the pathogenesis of HE, radionuclide studies are
not adequate for diagnostic purposes.
5. Principles of Treatment
5.1. General Treatment. Due to the lack of a pathogenetic
mechanism that explains the whole syndrome, therapy is
focused on correcting the precipitating factors and decreasing
plasma levels of ammonia and related metabolites. Most data
have not been evaluated in randomized clinical trials with
large number of patients. Study design is especially complex
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in this condition, as the clinical course of HE tends to resolve
and relapse spontaneously in many cases. The concurrence
of other disorders (anemia, electrolytic disturbances, fever,
severe infection, and alcoholic injury) is a confounding
factor that complicates the assessment of the neurological
manifestations. For these reasons,manymodalities of therapy
have been criticized. Nevertheless, in recent years there have
been several studies that render important data and that have
changed the management of the patient that develops HE.
The approach to the patient with overtHEmust guarantee
the vital support of the patient, correct the precipitating
event, and withdraw diuretics. The treatment of HE has
different targets that are responsible for the plasma rise of
toxic substances with potential effects on central nervous
system, with ammonia being the most relevant [85]. The best
results have been obtained in studies focused on prevention
of recurrence with lactulose, rifaximin, and HPN-100. Use of
these drugs in the episode of overt HE is extrapolated from
preventive studies.
5.2. Nutrition. Classically, the recommendation for patients
with HE has been to restrict dietary protein intake, but this
is a measure that nowadays is considered wrong. For several
decades it was recommended withholding all protein intake
and subsequently increasing the intake to maximal tolerance
[86]; however, this recommendation has no solid support
[87]. Only one randomized study has investigated the effects
of protein restriction on the outcome of HE [88]. In this
study, thirty patients admitted for an episode of HE received
progressive amounts of proteins (from 0 to 1.2 g⋅kg⋅d) or
normal protein amounts (1.2 g⋅kg⋅d) from the beginning.The
dietwas administered via nasogastric tube for 2weeks andHE
was assessed blinded for group of treatment. The main result
of the study was that there were no differences in the outcome
of HE, while the normal protein diet resulted metabolically
to be more adequate. Thus, restriction of proteins of the diet
does not appear to have any beneficial effect for episodic HE.
From this study the nutritional management of patients with
HE has changed radically. Although avoiding intake of large
amounts of protein may be positive to reduce toxins that are
involved in HE, restriction may worsen liver function and
increase the risk of death. A positive nitrogenous balancemay
improve encephalopathy by promoting hepatic regeneration
and increasing the capacity of muscle to detoxify ammonia.
For these reasons the current recommendation is to avoid
restrictions of dietary protein [87]. Patients are nowadays
treated with nutritional support that provides at least a dose
of protein of 0.8 gr/kg/d.
Some studies suggest that the type of protein may
influence the outcome. Branched chain amino acids were
promoted as a mechanism to correct the imbalance in the
plasma amino acid profile and thought to be involved in the
pathogenesis of hepatic encephalopathy. However, clinical
trials using branched chain amino acids have not shown
dramatically beneficial effects for episodes of HE. A new
analysis of several published studies, including some more
recent, supports a mild positive effect of BCAA on minimal
HE, whose clinical impact is debatable [89, 90].
Branched chain amino acids do not show significant
effects on survival. Critical reviews of the published studies
highlight the inadequate design of the majority of studies.
Considerations of cost-effectiveness indicate that branched
chain amino acids should not be used outside clinical trials
[91]. Branched-chain amino acids show anticatabolic effects
in patients with chronic liver diseases, probably due to their
ability to serve as an energy substrate for muscle and because
of their actions on muscle protein synthesis and degradation.
This nutritional effect may result in an improvement of liver
function and a better clinical outcome, as shown in a multi-
center trial performed in Italy that included patients with
advanced cirrhosis,most of themwithout priorHE [92],most
recent articles has shown no improvement in recurrence of
overtHE but has been effective in increasingmusclemass and
improving MHE [89].
5.3. Nonabsorbable Disaccharides. Lactulose (𝛽-galactosido-
fructose) and other nonabsorbable disaccharides were intro-
duced with the goal of promoting the growth of Lactobacillus
bifidus, which contains little urease activity and via this
mechanism could decrease the production of ammonia in
the colon. This is not its mechanism of action, which is still
complex and not fully understood.The bulk of evidence links
the efficacy of lactulose to an interaction with the enteric
flora and to a decrease in the generation of nitrogenous com-
pounds in the intestine [93]. Administered orally, lactulose is
not broken down by intestinal disaccharidases and reaches
the cecum, where it is metabolized by enteric bacteria to
lactate and acetate [94], causing a drop in cecal pH leading
to an increase in fecal nitrogen excretion and a decrease in
the amount of nitrogen that reaches portal blood [95].
The efficacy of lactulose has been demonstrated in the
primary and secondary prevention of hepatic encephalopa-
thy. Two studies conducted in India showedmarked improve-
ment in the recurrence of HE after approximately one year
of treatment with lactulose. The results of these studies have
led to considering the use of lactulose as a standard of care.
The efficacy is shown in the prevention, but its use has been
generalized to its treatment. Singularly, it is not known to
what extent the effect of lactulose is simply as a laxative and
whether other laxatives have similar benefits.There have been
additional studies showing a positive effect of nonabsorbable
disaccharides in HE, which were reviewed by Als Nielsen et
al. in 2004 [96]. While the studies showed an improvement
of HE, their quality was considered insufficient. Thus, while
there are no doubts in using lactulose or lactitol for prevent-
ing HE, it would be recommendable to perform new studies
with nonabsorbable disaccharides to show their efficacy in
the treatment of episodic HE. The use of disaccharides is
further supported on biological foundations and extensive
experience of use [2]. Treatment of minimal HE has shown
in several studies an improvement of neuropsychological tests
and quality of life indexes. However, the impact on clinically
relevant endpoints is a matter of debate and treatment of
minimal HE is not firmly established [96].
5.4. Antibiotics. The use of antibiotics in the treatment of
HE is based on its action in the intestinal flora. Apart from
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decreasing the bulk of intestinal flora, different mechanisms
have been proposed; they include inhibition of the activity
of intestinal glutaminase (enzyme that is activated in cir-
rhotic patients) and through thismechanismdecrease plasma
ammonia [97]. Another action is decreasing bacterial trans-
location and downregulating the immune response triggered
by these bacterial products [98].
Neomycin was the first antibiotic that was tested in the
treatment of HE that showed similar efficacy to lactulose in
chronic HE [99]. Since neomycin is an aminoglycoside, the
major concernwith its use is the potential of renal or auditory
toxicity. Absorption of neomycin is poor (<4%) and the drug
is considered potentially toxic only after long-term use.
Other antibiotics that were proposed were metronidazole
and vancomycin; their potential toxicity have led to abandon
them, especially in long-term use.
Rifaximin is an antibiotic with wide antibacterial action
and low intestinal absorption that is currently recommended
for the prevention of HE, especially because it has minimal
toxic effects that allow prolonged use. Studies that have
compared rifaximin (1200mg/d) to nonabsorbable disaccha-
rides (lactulose 45 to 120mL/day, lactitol 60mg/day) [100–
106] show a slightly better, but not significant, outcome for
rifaximin. Similar effects were also seen when comparing
rifaximin to neomycin (4500mg o 3000mg) [107–110] or par-
omomycin (1500mg/d) [111]. Significantly, only three of these
studies [100, 104, 106] were performed during an overt
episode of HE and none of them had a placebo group. Eltawil
et al. [112] included all these studies in a meta-analysis; the
comparison of rifaximin and disaccharides found that both
groups reach the primary endpoint (recovery of the HE
episode or clinically relevant improvement) without differ-
ences (OR = 1.92, 95% IC: 0.79–4.98, and 𝑃 = 0.15). Similar
results were found when comparing rifaximin with other
antibiotics (OR = 2.77, 95% IC: 0.35–21.83, and𝑃 = 0.21). No
differences were also found comparing rifaximin to nonab-
sorbable disaccharides or to other antibiotics (paromomycin
or neomycin). Nevertheless, there was a trend towards a
better outcome in favor of rifaximin (OR = 1.96, 95% IC:
0.94–4.08, and𝑃 = 0.07) [112]. Again no statistical differences
were observed in plasma ammonia [100, 104, 106, 108–111]
or improvement of psychometric tests [102, 106, 110] but
rifaximin exhibited a better safety profile (OR = 0.27, 95%
IC: 0.15–0.59, and 𝑃 < 0.01) based on a lower frequency of
diarrhea.
One study has compared rifaximin to placebo in the
secondary prevention of recurrent HE (at least 2 episodes
in 6 months). Since these patients corresponded to a highly
recurrent population, almost all patients (90%) were receiv-
ing in addition lactulose. The more important result is that
those that received rifaximin had a much lower number of
new episodes of HE in the following 6 months (22% versus
46%). Hospitalizations associated with HE was also lower
in the rifaximin group (13% versus 22%) [113]. Furthermore,
an analysis of the quality of life of these patients showed
that those with recurrent HE had lower scores on daily
life activities [114]. Based on these results, it is common to
recommend the use of lactulose or lactitol after the first
episode ofHE, in combinationwith rifaximin after the second
episode. It is not known whether rifaximin will also be
necessary in the prevention of recurrence in patients with
well-defined precipitating events that have been resolved (i.e.,
severe infection, dehydration, and renal failure).
In summary, rifaximin has been shown to be effective
in the prophylaxis of new HE episodes with dose 1200mg/d
combined with lactulose, but no studies comparing its
efficacy to placebo have been performed for assessing its
effectiveness during the episode of HE and no difference with
nonabsorbable disaccharides or other antibiotics has been
demonstrated in this clinical situation.
5.5.Modulators of AmmoniaMetabolism. Glycerol phenylbu-
tyrate (HPN-100) is a prodrug of phenylbutyric acid (PBA),
which is absorbed from the intestine and converted by way
of b-oxidation to the active moiety, phenylacetic acid (PAA).
PAA is conjugated with glutamine in the liver and kidney
by way of N-acyl coenzyme A-L-glutamine N-acyltransferase
to form phenylacetylglutamine (PAGN) and hydrosoluble
molecule that could be eliminated trough the urine. This
molecule has proven its safety in cirrhotic patients [115]. In
a recent randomized double-blind study, the administration
of a HPN-100, which enhanced the urinary excretion of
ammonia equivalents, resulted in a lower number of recur-
ring HE episodes. A significant number received rifaximin
in addition to HPN-100. In this subgroup, the combination
of rifaximin and HPN-100 did not show better results than
isolated rifaximin [116].
Ornithine phenylacetate (OP) is a new proposal for
decreasing ammonia in cirrhosis trough the combined
administration of PA and ornithine. This therapy is based
on the capacity of ornithine to stimulate the activity of
glutamine synthetase; hence, incorporating ammonia into
a “nontoxic” molecule. The newly formed glutamine will
combine with PA allowing the elimination of ammonia in
the urine by its conversion into PAGN.This strategy prevents
the degradation of glutamine by intestinal glutaminase and
avoids new formation of ammonia [117]. This molecule has
demonstrated to be safe in decompensate cirrhotic patients
and the current data seems to confirm its efficacy in decreas-
ing plasma ammonia [118].
5.6. Detoxifying Therapies. Extracorporeal albumin dialysis
has been proposed for improving the survival and treating
cirrhotic patients with severe decompensation or acute or
chronic liver failure (ACLF) [119]. There have been two trials
with the goal of reducing mortality of severely decompen-
sated cirrhosis: The RELIEF trial [120] and the HELIOS trial
[121]. Both were randomized studies that included a large
number of patients (𝑛 = 145 and 𝑛 = 189). Therapy with
extracorporeal systems did not show significant differences
in survival at 4 weeks. However, there were some positive
indicators (bilirubin, renal function, and degree of hepatic
encephalopathy) that support that these therapies may have
a niche in specific group of patients. A study using the
molecular adsorbent recirculating system (MARS) found a
more rapid improvement in the severity of HE, which has
been the basis for its approval for patients with severe HE
[120]. Albumin has also been proposed for onset HE in
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addition to laxatives and rifaximin; however, recently, there
were no differences in the outcome of HE between albumin
and placebo; however, survival in the follow-up was better in
the albumin group at 90 days [122].
5.7. Special Cases. Patients with a good liver function
(MELD< 12) and large portal-systemic shunts should be eval-
uated for possible occlusion of the shunt using angioradiolog-
ical embolization, which has been shown safe and effective
[123]. Embolization is tolerated in cirrhotic associated shunts
but should not be performed in congenital hypoplasia of the
portal vein to avoid massive upper gastrointestinal bleeding
post embolization [124].
Special attention must be given to patients who have
undergone placement of a transjugular intrahepatic portosys-
temic shunt (TIPS); one of themost relevant adverse events is
overt HE, which usually appear in 33% of the patients during
the first month after the placement. Some factors have been
associated with a higher HE risk (age over 65 years, previous
episodes of overtHE, andChild-PughC) but prophylactic use
of nonabsorbable disaccharides or rifaximin have not shown
to be effective during the first month after TIPS. For this
reason antiencephalopathy therapy is usually reserved for the
symptomatic patient [125].
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[4] D. Häussinger and F. Schliess, “Pathogenetic mechanisms of
hepatic encephalopathy,” Gut, vol. 57, no. 8, pp. 1156–1165, 2008.
[5] J. Roche Sicot, C. Sicot, and M. Peignoux, “Acute hepatic
encephalopathy in the rat: the effect of cross circulation,” Clin-
ical Science and Molecular Medicine, vol. 47, no. 6, pp. 609–615,
1974.
[6] R. F. Butterworth, “Altered glial-neuronal crosstalk: cornerstone
in the pathogenesis of hepatic encephalopathy,”Neurochemistry
International, vol. 57, no. 4, pp. 383–388, 2010.
[7] J. E. Fischer and R. J. Baldessarini, “False neurotransmitters and
hepatic failure,”The Lancet, vol. 2, no. 7715, pp. 75–80, 1971.
[8] R. F. Butterworth, “Hepatic encephalopathy: a neuropsychiatric
disorder involving multiple neurotransmitter systems,” Current
Opinion in Neurology, vol. 13, no. 6, pp. 721–727, 2000.
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[39] J. Córdoba, J. Gottstein, and A. T. Blei, “Chronic hyponatremia
exacerbates ammonia-induced brain edema in rats after porta-
caval anastomosis,” Journal of Hepatology, vol. 29, no. 4, pp. 589–
594, 1998.
[40] M. Y. Morgan, A. W. Jakobovits, I. M. James, and S. Sherlock,
“Successful use of bromocriptine in the treatment of chronic
hepatic encephalopathy,” Gastroenterology, vol. 78, no. 4, pp.
663–670, 1980.
[41] A. Michalak, C. Rose, J. Butterworth, and R. F. Butterworth,
“Neuroactive amino acids and glutamate (NMDA) receptors
in frontal cortex of rats with experimental acute liver failure,”
Hepatology, vol. 24, no. 4 I, pp. 908–913, 1996.
[42] J. Lavoie, J.-F. Giguere, G. P. Layrargues, and R. F. Butterworth,
“Amino acid changes in autopsied brain tissue from cirrhotic
patients with hepatic encephalopathy,” Journal of Neurochem-
istry, vol. 49, no. 3, pp. 692–697, 1987.
[43] A. H. Lockwood, E. W. H. Yap, H. M. Rhoades, and W. H.
Wong, “Altered cerebral blood flow and glucose metabolism
in patients with liver disease and minimal encephalopathy,”
Journal of Cerebral Blood Flow and Metabolism, vol. 11, no. 2,
pp. 331–336, 1991.
[44] R. E. O'Carroll, P. C. Hayes, K. P. Ebmeier et al., “Regional cere-
bral blood flow and cognitive funtion in patients with chronic
liver disease,”The Lancet, vol. 337, no. 8752, pp. 1250–1253, 1991.
[45] F. S. Larsen, “Cerebral circulation in liver failure: Ohm's law in
force,” Seminars in Liver Disease, vol. 16, no. 3, pp. 281–292, 1996.
[46] J. Cordoba and A. T. Blei, “Brain edema and hepatic encepha-
lopathy,” Seminars in Liver Disease, vol. 16, no. 3, pp. 271–280,
1996.
[47] J. P. Donovan, D. F. Schafer, B. W. Shaw Jr., and M. F. Sor-
rell, “Cerebral oedema and increased intracranial pressure in
chronic liver disease,”The Lancet, vol. 351, no. 9104, pp. 719–721,
1998.
[48] R. Jalan, S. W. M. O. Damink, N. E. P. Deutz, A. Lee, and P.
C. Hayes, “Moderate hypothermia for uncontrolled intracranial
hypertension in acute liver failure,” The Lancet, vol. 354, no.
9185, pp. 1164–1168, 1999.
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